SIREN : 411200165
ELAIAPHARM is a French company founded 29 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in VALBONNE (06560), this company of category ETI shows in 2024 a revenue of 40.0 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 39 962 657 € | 38 660 518 € | 37 940 923 € | 36 905 897 € | 33 947 195 € | 30 480 266 € | 28 520 262 € | 28 559 237 € | 28 446 375 € |
| Net income | 1 929 173 € | 1 626 098 € | 1 804 344 € | 1 576 029 € | 1 393 164 € | 376 865 € | 976 499 € | 1 137 164 € | 1 250 443 € |
| EBITDA | 8 909 650 € | 7 913 153 € | 8 103 369 € | 10 718 301 € | 8 116 592 € | 5 865 630 € | 6 268 102 € | 7 059 311 € | 6 605 869 € |
| Net margin | 4.8% | 4.2% | 4.8% | 4.3% | 4.1% | 1.2% | 3.4% | 4.0% | 4.4% |
In 2024, ELAIAPHARM achieves revenue of 40.0 M€. Revenue is growing positively over 9 years (CAGR: +4.3%). Vs 2023: +3%. After deducting consumption (9.9 M€), gross margin stands at 30.1 M€, i.e. a rate of 75%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 8.9 M€, representing 22.3% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 1.9 M€, i.e. 4.8% of revenue. This profit can be retained or distributed to shareholders.
39 962 657 €
30 053 172 €
8 909 650 €
2 640 144 €
1 929 173 €
22.3%
The debt ratio (= Financial debt / Equity x 100) stands at 58%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 52%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 1.4 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 26.5% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
57.871%
51.739%
26.486%
1.422
32.6%
In 2024, the debt ratio of ELAIAPHARM (57.87) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
In 2024, the financial autonomy of ELAIAPHARM (51.7%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of ELAIAPHARM (1.42) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 173.93. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 6.8x. Operating income very largely covers interest expenses: high safety margin.
173.93
6.822
In 2024, the liquidity ratio of ELAIAPHARM (173.93) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of ELAIAPHARM (6.8x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 42 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 117 days. Excellent situation: suppliers finance 75 days of the operating cycle (retail model). Inventory turnover is 80 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 99 days of revenue, i.e. 11.0 M€ to permanently finance.
11 031 292 €
42 j
117 j
80 j
99 j
Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 384 907€ to 1 183 054€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare ELAIAPHARM with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of ELAIAPHARM in 2024 is 40.0 M€.
Yes, ELAIAPHARM generated a net profit of 1.9 M€ in 2024.
The headquarters of ELAIAPHARM is located in VALBONNE (06560), in the department Alpes-Maritimes.
The tax return of ELAIAPHARM is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
ELAIAPHARM operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.